文献速递浆细胞疾病

CD86调控骨髓瘤细胞存活

CD86 regulates myeloma cell survival.
PubMed 文献 · Blood Adv · 2017-11-16

该研究探讨阻断CD28-CD86通路对骨髓瘤细胞存活的影响。沉默CD28或CD86可导致骨髓瘤细胞死亡,并下调整合素和已知骨髓瘤存活因子IRF4。CD86的促存活活性依赖其胞质结构域,提示靶向该通路是骨髓瘤有前景的治疗方向。

要点

  • 沉默CD28或CD86阻断CD28-CD86通路可导致骨髓瘤细胞死亡。
  • 抑制该通路可下调整合素和骨髓瘤存活因子IRF4。
  • CD86的促存活活性依赖其胞质结构域。

核心结论

  • 靶向CD28-CD86通路是骨髓瘤有前景的治疗方向,因其可调节细胞存活相关的多个过程。

主要发现

  • 通过沉默CD28或CD86阻断CD28-CD86通路可导致骨髓瘤细胞死亡。
  • 抑制该通路可下调整合素和已知骨髓瘤存活因子IRF4。
  • CD86作为该通路的经典配体,其促存活活性依赖其胞质结构域。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy. Here we show that blocking the CD28-CD86 pathway via silencing of either CD28 or CD86 leads to myeloma cell death. Inhibiting this pathway leads to downregulation of integrins and IRF4, a known myeloma survival factor. Our data also indicate that CD86, the canonical ligand in this pathway, has prosurvival activity that is dependent on its cytosolic domain. These findings indicate that targeting of this pathway is a promising therapeutic avenue for myeloma, because it leads to modulation of different processes important in cell viability.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gavile CM, Barwick BG, Newman S, et al. CD86 regulates myeloma cell survival. Blood Adv. 2017. PMID: 29296880. doi:10.1182/bloodadvances.2017011601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。